Join Inmagene Biopharmaceuticals for a virtual KOL event featuring Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), Maryanne Senna, MD (Beth Israel Lahey Health, Harvard Medical School), and Yufang Lu, MD, PhD (Inmagene), who will discuss the potential role of anti-OX40/OX40L monoclonal antibodies (mAbs) in the treatment of atopic dermatitis (AD) and alopecia areata (AA).

The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 – the only clinical-stage non-depleting anti-OX40 mAb.

A live question and answer session will follow the formal presentations.